The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammatory cortical demyelination in early multiple sclerosis.
Open accessAbstract
BACKGROUND: Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease. METHODS: We evaluated the prevalence and character of demyelinating cortical lesions in patients with multiple sclerosis. Cortical tissues were obtained in passing during biopsy sampling of white-matter lesions. In most cases, biopsy was done with the use of stereotactic procedures to diagnose suspected tumors. Patients with sufficient cortex (138 of 563 patients screened) were evaluated for cortical demyelination. Using immunohistochemistry, we characterized cortical lesions with respect to demyelinating activity, inflammatory infiltrates, the presence of meningeal inflammation, and a topographic association between cortical demyelination and meningeal inflammation. Diagnoses were ascertained in a subgroup of 77 patients (56%) at the last follow-up visit (at a median of 3.5 years). RESULTS: Cortical demyelination was present in 53 patients (38%) (104 lesions and 222 tissue blocks) and was absent in 85 patients (121 tissue blocks). Twenty-five patients with cortical demyelination had definite multiple sclerosis (81% of 31 patients who underwent long-term follow-up), as did 33 patients without cortical demyelination (72% of 46 patients who underwent long-term follow-up). In representative tissues, 58 of 71 lesions (82%) showed CD3+ T-cell infiltrates, and 32 of 78 lesions (41%) showed macrophage-associated demyelination. Meningeal inflammation was topographically associated with cortical demyelination in patients who had sufficient meningeal tissue for study. CONCLUSIONS: In this cohort of patients with early-stage multiple sclerosis, cortical demyelinating lesions were frequent, inflammatory, and strongly associated with meningeal inflammation. (Funded by the National Multiple Sclerosis Society and the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation (Bo et al., 2004; Brink et al., 2005; van Horssen et al., 2007), although early lesions have been associated with prominent microglial activation (Lucchinetti et al., 2011).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“Biopsies taken from early MS patients with cortical demyelination were more likely to have leptomeningeal inflammation, consisting of effector T cells and IgA B cells infiltrates, than those without cortical demyelination.”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“The leptomeninges are now recognized as a key player in multiple sclerosis (MS), an inflammatory CNS autoimmune disorder characterized by axon demyelination”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMagliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Flagged first, then by citations
Research works printed but not linked: 1
- Tardif CL, 2010, Med Image Comput Assist Interv, 13, 181
Cited by
Sorted by citations
Items 701–800 of 1,000
Metabolic costs of walking and arm reaching in persons with mild multiple sclerosis
Courter, R. J., Álvarez, E., Enoka, R. M., & Ahmed, A. A. (2023) · Journal of Neurophysiology · doi:10.1152/jn.00373.2022 · Cited by 10
Revisión de la esclerosis múltiple (1). A propósito de un caso
Martinez-Altarriba, M. C., Ramos‐Campoy, O., Luna-Calcaño, I. M., & Arrieta-Antón, E. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.07.009 · Cited by 10
Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
Zivadinov, R., Dwyer, M. G., Carl, E. M., Poole, E. M., Cavalier, S., Briassouli, P., & Bergsland, N. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420970754 · Cited by 10
Koshihara, H., Oguchi, K., Takei, Y., Kitazawa, K., Higuchi, K., & Ohara, S. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.08.037 · Cited by 10
Mistry, N., Hobart, J. C., Rog, D. J., Muhlert, N., Mathews, J., Baker, D., & Giovannoni, G. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105706 · Cited by 9
Yao, T.-F., Wang, Z., Sun, L., Yu, S., Yu, H., Yang, Z.-Z., Li, W., Niu, L., Sun, D., Shi, Y.-H., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108137 · Cited by 10
Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS
Blok, K. M., Kranenbarg, R. A. M. K., Ananth, K., Engelenburg, H. J., van den Bosch, A. M. R., Giannini, L., de Beukelaar, J., Seelaar, H., Huitinga, I., Green, A., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70052 · Cited by 10
Inflammation’s impact on the interaction between oligodendrocytes and axons
Green, T. R. F., Pingen, M., & Edgar, J. M. (2025) · Discovery Immunology · doi:10.1093/discim/kyaf008 · Cited by 11
Lin, C.-H., Scheller, A., Liu, Y., Krause, E., & Chang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043166 · Cited by 9
A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis
Dahal, S., Allette, Y. M., Naunton, K., & Harrison, D. M. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105344 · Cited by 9
The role of MRI in the evaluation of secondary progressive multiple sclerosis
Brown, J. W. L., & Chard, D. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1134323 · Cited by 10
Spring cleaning: time to rethink imaging research lines in MS?
Absinta, M., Reich, D. S., & Filippi, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8060-0 · Cited by 10
Autoinflammatory grey matter lesions in humans
Junker, A., & Brück, W. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283534a8a · Cited by 9
Self-citationPoorebrahim, M., Asghari, M., Abazari, M. F., Askari, H., Sadeghi, S., Taheri‐Kafrani, A., Nasr‐Esfahani, M. H., Ghoraeian, P., Aleagha, M. N., Arab, S. S., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.028 · Cited by 9
Comparison of olfactory function between neuromyelitis optica and multiple sclerosis
Li, L., Guo, H.-Y., Zhao, N., Zhang, L., Zhang, N., Liu, J., & Yang, L. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1424152 · Cited by 9
Donadieu, M., Kelly, H. M., Szczupak, D., Lin, J., Song, Y., Yen, C. C., Ye, F. Q., Kolb, H., Guy, J. R., Beck, E., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa235 · Cited by 9
Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis
Zhang, Y., Gu, J., Wang, X., Li, L., Fu, L.-L., Wang, D., Wang, X., & Han, X. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2042690 · Cited by 9
Feki, S., Damak, M., Sakka, S., Ali, Y. B., Mejdoub, S., Bouattour, N., Hachicha, H., Mhiri, C., & Masmoudi, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-19811-3 · Cited by 10
Actualités dans le diagnostic et la prise en charge thérapeutique de la sclérose en plaques
Depaz, R., Aboab, J., & Gout, O. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.02.011 · Cited by 9
Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?
Silva, B. A., & Ferrari, C. C. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0017 · Cited by 10
Crescenzo, F., Marastoni, D., Zuco, C., Pitteri, M., Magliozzi, R., Monaco, S., & Calabrese, M. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.11.009 · Cited by 9
Adverse childhood experiences predict reaction to multiple sclerosis diagnosis
Eilam‐Stock, T., Links, J., Khan, N., Bacon, T. E., Zuniga, G., Laing, L., Sammarco, C. L., Sherman, K., & Charvet, L. E. (2021) · Health Psychology Open · doi:10.1177/20551029211052830 · Cited by 10
Zheng, W., Chen, Y., Chen, H., Xiao, W., Liang, Y., Wang, N., Jiang, X. M., & Wen, S. (2018) · Neurological Research · doi:10.1080/01616412.2018.1497253 · Cited by 9
Can leptomeningeal enhancement be linked to multiple sclerosis?
Barkhof, F., & Reich, D. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001292 · Cited by 9
Cacciaguerra, L., Rocca, M. A., & Filippi, M. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2023.0360 · Cited by 10
Krijnen, E. A., van Dam, M., Bajrami, A., Bouman, P. M., Noteboom, S., Barkhof, F., Uitdehaag, B. M. J., Steenwijk, M. D., Klawiter, E. C., Koubiyr, I., et al. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52261 · Cited by 8
Automatic segmentation of spinal cord lesions in MS: A robust tool for axial T2-weighted MRI scans
Karthik, E. N., McGinnis, J., Wurm, R., Rühling, S., Graf, R., Valošek, J., Benveniste, P., Lauerer, M., Talbott, J. F., Bakshi, R., et al. (2025) · Imaging Neuroscience · doi:10.1162/imag.a.45 · Cited by 10
Cladribine tablets in the new multiple sclerosis era
Buttari, F., Dolcetti, E., Rizzo, F. R., Rizzi, C., Lauritano, G., Borrelli, A., Azzolini, F., Fantozzi, R., Assogna, F., Conte, A., et al. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251342855 · Cited by 9
Calvi, A., Vivó, F., Solana, E., López-Soley, E., Kanber, B., Albà-Arbalat, S., Sepúlveda, M., Martínez‐Hernández, E., Cabrera‐Maqueda, J. M., Fonseca, E. G., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-335884 · Cited by 9
Brain proteome‐wide association study linking‐genes in multiple sclerosis pathogenesis
Jia, T., Ma, Y., Qin, F., Han, F., & Zhang, C. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51699 · Cited by 8
Dünschede, J., Ruschil, C., Bender, B., Mengel, A., Lindig, T. M., Ziemann, U., & Kowarik, M. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030739 · Cited by 9
Silva, R. V., Morr, A. S., Herthum, H., Koch, S., Mueller, S. G., Batzdorf, C. S., Bertalan, G., Meyer, T., Tzschätzsch, H., Kühl, A. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02658-x · Cited by 8
Mahdaoui, S. E., Hansen, M. M., Hansen, M. B., Hvalkof, V. H., Søndergaard, H. B., Mahler, M. R., Christensen, J. R., Sellebjerg, F. T., & von Essen, M. R. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110262 · Cited by 9
Grzegorski, T., & Losy, J. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0084 · Cited by 9
DiSano, K. D., Linzey, M. R., Welsh, N. C., Meier, J. S., Pachner, A. R., & Gilli, F. (2020) · Journal of Visualized Experiments · doi:10.3791/61166 · Cited by 8
Silva, B. A., Miglietta, E. A., & Ferrari, C. C. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102845 · Cited by 8
Golan, M., Krivitsky, A., Mausner-Fainberg, K., Benhamou, M., Vigiser, I., Regev, K., Kolb, H., & Karni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042182 · Cited by 9
New and emerging immune‐targeted drugs for the treatment of multiple sclerosis
Palmer, A. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12285 · Cited by 8
Bernstock, J. D., Verheyen, J., Huang, B. Y., Hallenbeck, J. M., & Pluchino, S. (2014) · InTech eBooks · doi:10.5772/58599 · Cited by 9
Shriver, L. P., Plummer, E. M., Thomas, D. M., Ho, S. B., & Manchester, M. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20521e · Cited by 8
Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis
Karmon, Y., Morrow, S. A., Weinstock, A., Hojnacki, D. W., & Weinstock‐Guttman, B. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.05.039 · Cited by 8
Pineles, S. L., & Balcer, L. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-34044-1.00005-5 · Cited by 8
Newland, P., Salter, A. R., Flach, A., Flick, L. H., Thomas, F. P., Gulick, E. E., Rantz, M., & Skubic, M. (2019) · Rehabilitation Nursing · doi:10.1097/rnj.0000000000000210 · Cited by 8
Woitek, R., Leutmezer, F., Dal‐Bianco, A., Furtner, J., Kasprian, G. J., Prayer, D., & Schöpf, V. (2019) · Acta Radiologica · doi:10.1177/0284185119852735 · Cited by 8
The Role of Th17 Cells in Immunopathogenesis of Neuroinflammatory Disorders
Pourgholaminejad, A., & Tahmasebinia, F. (2019) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-19515-1_3 · Cited by 8
The therapeutic potential of bilobalide on experimental autoimmune encephalomyelitis (EAE) mice
Miao, Q., Zhang, X., Han, Q.-X., Ren, S.-S., Sui, R., Yu, J., Wang, J., Wang, Q., Yu, J., Cao, L., et al. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00555-w · Cited by 8
Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration
Sharma, V. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05348-9 · Cited by 7
The meninges as a neuroimmune interface: structure, barriers and roles in CNS disease
Joost, S., Kaddatz, H., Vankriekelsvenne, E., & Brandenburg, L. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00795-5 · Cited by 7
In vivo detection of connectivity between cortical and white matter lesions in early MS
Tillema, J., Weigand, S. D., Mandrekar, J. N., Shu, Y., Lucchinetti, C. F., Pirko, I., & Port, J. D. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516671027 · Cited by 7
Self-citationA Neuroprimer: Principles of Central Nervous System Immunity
Owens, G. P. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.08.004 · Cited by 8
Cortical projection neurons as a therapeutic target in multiple sclerosis
Beutel, T., Dzimiera, J., Kapell, H., Engelhardt, M., Gass, A., & Schirmer, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1842358 · Cited by 7
Kassis, I., Ben-Zwi, M., Petrou, P., Halimi, M., & Karussis, D. M. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.03.003 · Cited by 7
Tagge, I., Anderson, V. C., SPRINGER, C. S. J., Sammi, M. K., BOURDETTE, D. N., Spain, R., & Rooney, W. D. (2021) · Journal of Neuroimaging · doi:10.1111/jon.12912 · Cited by 7
The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation
Volonté, C., Apolloni, S., & Amadio, S. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_240 · Cited by 7
Fuchs, L., Mausner-Fainberg, K., Luban, A., Asseyer, S., Golan, M., Benhamou, M., Volovitz, I., Regev, K., Vigiser, I., Piura, Y. D., et al. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577936 · Cited by 7
Maxwell, D. L., & Orian, J. M. (2023) · Journal of Central Nervous System Disease · doi:10.1177/11795735231211508 · Cited by 8
How can proteomics elucidate the complexity of multiple sclerosis?
Farias, A. S., & dos Santos, L. M. B. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400171 · Cited by 7
Improving animal models for nervous system disorders
Brown, R. E. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00808.x · Cited by 8
Moroso, A., Ruet, A., Lamargue-Hamel, D., Munsch, F., Deloire, M., Ouallet, J., Cubizolle, S., Charré‐Morin, J., Saubusse, A., Tourdias, T., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.11.037 · Cited by 7
New onset seizures as a sole clinical presentation of multiple sclerosis
Hussona, M. A., KEARNEY, H. F., Fisher, A., Lynch, J. A., Looby, S. T., & Delanty, N. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518781994 · Cited by 7
The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia
Ooi, S., Kalinčík, T., Perucca, P., & Monif, M. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217321989767 · Cited by 7
Remote regulation of type 2 immunity by intestinal parasites
Popple, S., Burrows, K., Mortha, A., & Osborne, L. C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101530 · Cited by 7
Nitsch, L., Petzinna, S. M., Zimmermann, J., Getts, D. R., Becker, A. J., & Müller, M. (2022) · NeuroMolecular Medicine · doi:10.1007/s12017-022-08705-2 · Cited by 7
Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
Patel, C., Zagon, I. S., Thomas, G. A., & McLaughlin, P. J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91010 · Cited by 8
Deep grey matter involvement in multiple sclerosis: key player or bystander?
Kawachi, I. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308221 · Cited by 7
Blenkle, A., Geladaris, A., & Weber, M. S. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01647-w · Cited by 6
Advances in Multiple Sclerosis
Hauser, S. L. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2501195 · Cited by 7
Muñoz, Ú., Sebal, C., Escudero, E., Urcelay, E., Arroyo, R., García‐Martínez, M. Á., Quintana, F. J., Álvarez‐Lafuente, R., & Sádaba, M. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-16218-y · Cited by 6
Li, Y., Noto, D., Hoshino, Y., Mizuno, M., Yoshikawa, S., & Miyake, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-36532-3 · Cited by 6
Shirani, A., Stüve, O., & Cross, A. H. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.06.001 · Cited by 6
Nguyen, K. L., Bhatt, I. J., Gupta, S., Showkat, N., Swanson, K. A., Fischer, R., Kontermann, R. E., Pfizenmaier, K., Bracchi-Ricard, V. C., & Bethea, J. R. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110885 · Cited by 7
Messmer, M. L., Salapa, H. E., Popescu, B. F. G., & Levin, M. C. (2024) · Annals of Neurology · doi:10.1002/ana.27114 · Cited by 6
Self-citationOkutan, B., Frederiksen, J. L., Houen, G., Sellebjerg, F. T., Kyllesbech, C., Magyari, M., Paunovic, M., Sørensen, P. S., Jacobsen, C., Lassmann, H., et al. (2024) · Brain Pathology · doi:10.1111/bpa.13314 · Cited by 7
Self-citationβ-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis
Patel, C., Thomas, G. A., Zomorodi, N., Zagon, I. S., & McLaughlin, P. J. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102868 · Cited by 6
Plattén, M., Ouellette, R., Herranz, E., Barletta, V. T., Treaba, C. A., Mainero, C., & Granberg, T. (2022) · Journal of Neuroimaging · doi:10.1111/jon.12977 · Cited by 6
Advances in Imaging Multiple Sclerosis
Caverzasi, E., Cordano, C., Hauser, S. L., Henry, R. G., & Bischof, A. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1607278 · Cited by 6
Postmortem magnetic resonance imaging
Jonkman, L. E., & Geurts, J. J. G. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63639-3.00023-2 · Cited by 6
Faizy, T. D., Broocks, G., Thaler, C. P., Rauch, G., Gebert, P., Stürner, K. H., Flottmann, F., Leischner, H., Kniep, H. C., Stellmann, J., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00133 · Cited by 6
Clark, K. C., Wang, D., Kumar, P., Mor, S., Kulubya, E. S., Lazar, S. V., & Wang, A. (2022) · Advanced Biology · doi:10.1002/adbi.202101099 · Cited by 6
Xie, Y. H., Zhang, Y., Yao, Y., Liu, D., Chen, B., & Zhu, W. (2022) · European Radiology · doi:10.1007/s00330-022-08779-3 · Cited by 6
Chen, L., Tsang, J. Y., Ni, Y., Chan, S., Chan, K.-F., Zhang, S., & Tse, G. M.-K. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203334 · Cited by 6
Sastre‐Garriga, J. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516644677 · Cited by 6
Ashtiani, S. N. M., Behnam, H., Daliri, M. R., Hossein‐Zadeh, G., & Mehrpour, M. (2019) · Australasian Physical & Engineering Sciences in Medicine · doi:10.1007/s13246-019-00790-1 · Cited by 6
Demyelination in experimental intraventricular neurocysticercosis
Moura, V. B. L., Milhomem, A. C., Lima, S. B., Silva, H. M., Sugita, D. M., Vinaud, M. C., & Júnior, R. D. S. L. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190155 · Cited by 6
The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis
Kalinin, I. V., Makshakov, G., & Evdoshenko, E. P. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6513 · Cited by 6
MS progression is predominantly driven by age-related mechanisms – NO
McGinley, M., & Ontaneda, D. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518819712 · Cited by 6
The cortical blood–brain barrier in multiple sclerosis: a gateway to progression?
Bell, J. S., Spencer, J. I., Yates, R. L., & DeLuca, G. C. (2018) · Journal of Neurology · doi:10.1007/s00415-017-8727-1 · Cited by 6
Zhang, Q., Du, Y., Cao, J.-J., Yang, Y., Wu, W., Xu, W., Xiao, B., & Wei, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114800 · Cited by 5
Mousavi, P., Emadzadeh, M., Karimikhoshnoudian, B., Sahraian, M. A., Ghaffari, M., Shaygannejad, V., Payere, M., Baghaei, A., Zabeti, A., & Nahayati, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04347-w · Cited by 5
Panchal, D., Solanki, D., Solanki, R., Yadav, A. K., Bhatia, D. D., & Yadav, P. K. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00245 · Cited by 6
Liu, J., Peng, H., Yu, T., Huang, Y., Tan, N., Pang, L., Wu, Y., & Wang, L. (2023) · Pancreatology · doi:10.1016/j.pan.2023.08.005 · Cited by 5
Berek, K., Hegen, H., Auer, M., Barket, R., Pauli, F. D., Hocher, J., Krajnc, N., Zinganell, A., Deisenhammer, F., Berger, T., et al. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231201093 · Cited by 5
Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging
Zivadinov, R., Schweser, F., Jakimovski, D., Bergsland, N., & Dwyer, M. G. (2024) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.03.007 · Cited by 5
Cortical CD200–CD200R and CD47–SIRPα expression is associated with multiple sclerosis pathology
van den Bosch, A. M. R., Wever, D. D., Schonewille, P., Schuller, S. L., Smolders, J., Hamann, J., & Huitinga, I. (2024) · Brain Communications · doi:10.1093/braincomms/fcae264 · Cited by 5
Multiple Sclerosis: Pathogenesis Mechanism and Biomarkers
Arya, A., Dhall, M., Mittal, V., Kaushik, D. K., Mudgal, P., Kumar, T., Pandey, M., Kadian, R., Sharma, P., Rani, N., et al. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249307633240817160735 · Cited by 5
Lymphotoxin-dependent elevated meningeal CXCL13:BAFF ratios drive gray matter injury
Naouar, I., Pangan, A., Zuo, M., Raza, S. A., Champagne-Jorgensen, K., Patel, J., Wang, A. A., Pu, A., Ward, L. A., Ahn, J. S. Y., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02359-5 · Cited by 5
Multiple sclerosis enters a grey area
Pappalardo, J. L., & Hafler, D. A. (2019) · Nature · doi:10.1038/d41586-019-00563-6 · Cited by 5
Hyper-reflective foci changes in RRMS under natalizumab therapy
Puthenparampil, M., Basili, E., Ponzano, M., Mauceri, V. A., Miscioscia, A., Pilotto, E., Perini, P., Rinaldi, F., Bovis, F., & Gallo, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1421755 · Cited by 5
In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis
Krijnen, E. A., Lee, H., Noteboom, S., Chiang, F. L., Steenwijk, M. D., Schoonheim, M. M., Klawiter, E. C., & Huang, S. Y. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52237 · Cited by 5
Blaylock, R. L. (2025) · Surgical Neurology International · doi:10.25259/sni_1114_2024 · Cited by 5
Metadata
- Authors
- Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M.
- Affiliations
- Mayo Clinic (US)
- Cleveland Clinic Research (US)
- Medical University of Vienna (AT)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2188-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3282172
- OpenAlex
- W2113948549
- Cited by
- 1,103
- References
- 50
- Citations by year
- 2026: 37 · 2025: 44 · 2024: 69 · 2023: 70 · 2022: 68 · 2021: 104 · 2020: 75 · 2019: 83 · 2018: 64 · 2017: 72 · 2016: 75 · 2015: 84 · 2014: 89 · 2013: 100 · 2012: 67
- FWCI
- 58.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Multiple Sclerosis Society (RG3185-B-3)
- Multiple Sclerosis Society
- National Institutes of Health (P50NS38667)
- National Institute of Neurological Disorders and Stroke (P50NS38667, P50NS038667, R01NS049577)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, cortical demyelination, inflammatory demyelination, meningeal inflammation, cortical lesions, early multiple sclerosis, white matter lesions, stereotactic biopsy, disease progression
- MeSH terms
- Biopsy, Cerebral Cortex, Humans, Inflammation, Multiple Sclerosis, Prevalence, Logistic Models, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
